Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

Article  PubMed  Google Scholar 

Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer. 2008;113(2):293–301.

Article  PubMed  Google Scholar 

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024;390(15):1359–71.

Article  PubMed  Google Scholar 

Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2022;400(10358):1103–16.

Article  Google Scholar 

Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25(8):1038–52.

Article  PubMed  Google Scholar 

Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. The Lancet. 2023;401(10379):821–32.

Article  Google Scholar 

Bex A, Russo P, Tomita Y, Cutuli H, Rojas C, Gross-Goupil M, et al. Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from Part B of the randomized, phase 3 CheckMate 914 trial. J Clin Oncol. 2024;42(4_Suppl):LBA358.

Article  Google Scholar 

De Sousa LA, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep. 2019;9(1):11472.

Article  Google Scholar 

Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and safety between anti-PD-1 and anti-PD-L1 immunotherapy: the state-of-the-art review and future perspectives. Front Pharmacol. 2021;12: 714483.

Article  PubMed  PubMed Central  Google Scholar 

Penkov K, Uemura H, Campbell MT, Kollmannsberger CK, Lee JL, Venugopal B, et al. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. J Clin Oncol. 2024;42(16_Suppl):4508.

Article  Google Scholar 

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–80.

Article  PubMed  Google Scholar 

Motzer RJ, Russo P, Grünwald V, Tomita Y, Barthélémy P, Goh JC, et al. Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: subgroup analyses from the phase 3 CheckMate 914 (part A) trial. J Clin Oncol. 2023;41(16_suppl):4506.

Article  Google Scholar 

Ventriglia J, Passarelli A, Pisano C, Cecere SC, Rossetti S, Feroce F, et al. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: an analysis of the literature. Crit Rev Oncol Hematol. 2023;188: 104036.

Article  PubMed  Google Scholar 

Ben-David R, Alerasool P, Kalola H, Tillu N, Almoflihi M, Tsao CK, et al. Tumor characteristics associated with preoperatively detectable tumor-informed circulating tumor DNA in patients with renal masses suspicious for renal cell carcinoma. JCO Precis Oncol. 2024;8: e2400281.

Article  PubMed  Google Scholar 

Correa AF, Kalashnikova E, Wu HT, Winters RM, Balcioglu M, Sudhaman S, et al. Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma. Oncologist. 2024;29(10):887–93.

Article  PubMed  PubMed Central  Google Scholar 

Xu W, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, et al. Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: a trial of the ECOG-ACRIN Research Group (E2805). Clin Cancer Res. 2021;27(12):3397–403.

Article  PubMed  PubMed Central  Google Scholar 

Albiges L, Bex A, Suárez C, Uzzo R, Tang X, Assaf ZJ, et al. Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection. J Clin Oncol. 2024;42(16_suppl):4506.

Article  Google Scholar 

Vemula SV, Xu W, Wang Y, Liu X, de Somocurcio JR, McDermott D, et al. Abstract 5151: High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma. Cancer Res. 2024;84(6_Supplement):5151.

Article  Google Scholar 

Saliby RM, Saad E, Kashima S, Schoenfeld DA, Braun DA. Update on biomarkers in renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2024;44(2): e430734.

Article  PubMed  Google Scholar 

Zhu Z, Jin Y, Zhou J, Chen F, Chen M, Gao Z, et al. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Mol Cancer. 2024;23(1):146.

Article  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022;10(3): e004316.

Article  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803-817.e4.

Article  PubMed  PubMed Central  Google Scholar 

Smith CC, Beckermann KE, Bortone DS, Cubas AAD, Bixby LM, Lee SJ, et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest. 2019;128(11):4804–20.

Article  Google Scholar 

Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022;55(3):527-541.e5.

Article  PubMed  Google Scholar 

Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024;35(11):1026–38.

Article  PubMed  Google Scholar 

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41.

Article  PubMed  PubMed Central  Google Scholar 

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300.

Article  PubMed  Google Scholar 

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27.

Article  PubMed  Google Scholar 

Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Urol. 2023;84(5):449–54.

Article  PubMed  Google Scholar 

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. 2024;42(11):1222–8.

Article  PubMed  Google Scholar 

Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, et al. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): final follow-up results from the CheckMate 9ER trial. J Clin Oncol. 2025;43(5_suppl):439–439.

Article  Google Scholar 

Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 2024;9(5): 102994.

Article  PubMed  PubMed Central  Google Scholar 

Albiges L, Rodriguez CS, Procopio G, Bex A, Gruenwald V, Schmidinger M, et al. 1717TiP CARE1 pragmatic clinical trial: first line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma. Ann Oncol. 2024;35:S1029.

Article  Google Scholar 

Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. C